Vortioxetine for the Treatment of Depression in Patients with Parkinson's Disease: A 16-week Pilot, Prospective, Open-label Safety Study
Vortioxetine is a safe and well-tolerated therapeutic approach for depression in Parkinson's disease. As a secondary objective, an improvement in depressive symptoms was observed. However, the study's open-label design and small sample size limit the generalizability of the findings.
Authors
- Daniele Bravi
- Cecilia Coletti (ORCID: https://orcid.org/0000-0002-3609-290X)
- Laura Vacca (ORCID: https://orcid.org/0000-0002-6634-4119)
- Fabrizio Stocchi (ORCID: https://orcid.org/0000-0002-5763-0033)
- Fabiana Giada Radicati (ORCID: https://orcid.org/0000-0001-9930-6656)
Institutions
- Vita-Salute San Raffaele University (IT)
- San Raffaele University of Rome (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Current Neuropharmacology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.2174/011570159x361647250416072053
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78